Bleomycin-induced pulmonary fibrosis is the most common experimental study model of human lung fibrosis.
Our scientists have developed a mouse bleomycin-induced lung fibrosis and established time courses of effect over a 28-day period post-bleomycin administration.
We have the capability to administer compounds by multiple routes (e.g., oral, inhalation, intravenous, subcutaneous), and efficacy is then monitored by a number of methods:
Histopathology and qualification via a modified Ashcroft score (n=10)
Collagen quantification (directly or via image analysis of lung sections)
Bronchoalveolar fluid (BALF) analysis (separate group of n=10)